Biological process  Protein metabolism
 Molecular function  Protease inhibitor activity
 
Protein   alpha-2-macroglobulin  Gene symbol   A2M
 
 Cellular component  
     
 
Component
Cytosol
Extracellular
 
   
 
Experimental evidence   
  Total number of studies : 51    
 
Peptide sequence Method Platform  Sample  Reference
Immunoassay - Plasma Haab et al. 2005
Mass spectrometry LTQ-Orbitrap Plasma Schenk et al. 2008
Mass spectrometry LTQ Plasma Looze et al. 2008
Mass spectrometry Q-TOF Plasma Bastos-Amador et al. 2012
Mass spectrometry LTQ Orbitrap Velos Plasma Kalra et al. 2013
Multiple reaction monitoring - Plasma Percy et al. 2013
Single radial immunodiffusion - Serum Storiko et al. 1968
Multiple reaction monitoring 6490 QQQ Blood Chambers et al. 2012
Multiple reaction monitoring 6490 QQQ Plasma Domanski et al. 2012
Multiple reaction monitoring 6490 QQQ Plasma Percy et al. 2012
Multiple reaction monitoring 4000 QTRAP Plasma Kuzyk et al. 2009
Multiple reaction monitoring 4000 QTRAP Plasma Anderson et al. 2009
Multiple reaction monitoring TSQ Vantage Plasma Huttenhain et al. 2012
Multiple reaction monitoring 6490 QQQ Plasma Percy et al. 2013
Mass spectrometry LCQ DecaXP Serum Tirumalai et al. 2003
Mass spectrometry Plasma Liu et al. 2007
Mass spectrometry LCQ Duo Serum Gundry et al. 2007
Mass spectrometry LTQ FT Plasma Jia et al. 2009
Mass spectrometry 4800 Plus MALDI TOF/TOF Plasma Madian et al. 2010
Mass spectrometry API QSTAR Pulsar i Plasma Wasinger et al. 2005
Mass spectrometry Fourier transform ion cyclotron resonance (FT_ICR) Plasma Qian et al. 2010
Mass spectrometry LTQ Orbitrap XL Plasma Panchaud et al. 2009
Mass spectrometry 6340 Ion Trap LC/MS Plasma Zhang et al. 2008
Mass spectrometry LTQ Orbitrap XL Plasma Kang et al. 2010
2-D DIGE - Plasma Corzett et al. 2010
Chromatography - Plasma Van et al. 1993
ELISA - Plasma Krimbou et al. 1998
Mass spectrometry MALDI-TOF/TOF Serum Misek et al. 2005
Mass spectrometry - Plasma Michel et al. 2006
Mass spectrometry LTQ linear ion trap & Micromass Q-TOF API US Plasma Sleat et al. 2006
Mass spectrometry Finnigan LTQ MS Plasma Okano et al. 2006
Mass spectrometry IMS-TOF Plasma Valentine et al. 2006
Mass spectrometry MALDI-TOF Plasma Manabe et al. 2007
Mass spectrometry Q-TOF Plasma Kim et al. 2007
Mass spectrometry IMS-TOF Plasma Manabe et al. 2007
Mass spectrometry LTQ FT Serum Sennels et al. 2007
Mass spectrometry Agilent XCT plus Serum Stempfer et al. 2008
Mass spectrometry Agilent 1100 LC/MSD Trap XCT Plus System Plasma Ahrends et al. 2009
Mass spectrometry 4800 Plus MALDI TOF/TOF Plasma Kolla et al. 2009
Mass spectrometry 4800 Plus MALDI TOF/TOF Plasma Jeong et al. 2010
Mass spectrometry MALDI-TOF Plasma Insenser et al. 2010
Mass spectrometry MALDI-TOF Plasma Darde et al. 2010
Mass spectrometry LTQ FT Plasma Prentice et al. 2010
Mass spectrometry LTQ Plasma Tu et al. 2010
Mass spectrometry LTQ Orbitrap Plasma Shuford et al. 2010
Mass spectrometry MALDI-TOF/TOF Plasma Ignjatovic et al. 2011
Mass spectrometry LTQ Orbitrap XL Serum Sinclair et al. 2011
Mass spectrometry 4800 Proteomics Analyzer Plasma Bouwman et al. 2011
Mass spectrometry - Plasma Farrah et al. 2011
Mass spectrometry LCQ Deca XP Plus Plasma/Serum Yang et al. 2005
Mass spectrometry LCQ DECA XP Serum Yang et al. 2004
 
   
 
 Multiple reaction monitoring data  
     
 
Peptide sequence MH+ Sample Number of studies Reference
LLIYAVLPTGDVIGDSAK  1844  Plasma  Kuzyk et al. 2009
LLIYAVLPTGDVIGDSAK  1851  Plasma  Domanski et al. 2012
LLIYAVLPTGDVIGDSAK  1845  Plasma  Domanski et al. 2012
TEHPFTVEEFVLPK  1678.8  Plasma  Domanski et al. 2012
TEHPFTVEEFVLPK  1672.8  Plasma  Domanski et al. 2012
LLIYAVLPTGDVIGDSAK  1845  Plasma  Percy et al. 2012
LLIYAVLPTGDVIGDSAK  1845  Blood  Chambers et al. 2012
LPPNVVEESAR  1210.6  Plasma  McKay et al. 2007
QTVSWAVTPK  1116.6  Plasma  McKay et al. 2007
SASNMAIVDVK  1134.5  Plasma  McKay et al. 2007
NEDSLVFVQTDK  1394.6  Plasma  McKay et al. 2007
AIGYLNTGYQR  1255.6  Plasma  McKay et al. 2007
DMYSFLEDMGLK  1448.6  Plasma  McKay et al. 2007
SSSNEEVMFLTVQVK  1697.8  Plasma  Huttenhain et al. 2012
TEHPFTVEEFVLPK  1672.8  Plasma  Percy et al. 2012
LLIYAVLPTGDVIGDSAK  1845  Plasma  Anderson et al. 2009
TEHPFTVEEFVLPK  1672.8  Plasma  Percy et al. 2013
 
   
 
  Protein concentration    
     
 
Protein concentration Method Sample
Reference
1.4  mg/ml Immunoassay  Plasma Haab et al. 2005
1.4  mg/ml Plasma Panchaud et al. 2009
1.4  mg/ml Plasma Tu et al. 2010
1.609  mg/ml Multiple reaction monitoring  Plasma Percy et al. 2013
1.8  mg/ml Plasma Polanski et al. 2007
1.8  mg/ml Plasma Gundry et al. 2007
2  mg/ml Plasma Wu et al. 2003
2  mg/ml Plasma Qian et al. 2005
220  μg/ml Spectral counting  Plasma Farrah et al. 2011
1800  μg/ml Plasma Anderson et al. 2004
2756.02  μg/ml Multiple reaction monitoring  Blood Chambers et al. 2012
1.6-3.8  mg/ml Plasma Shen et al. 2004
1300-3800  μg/ml Single radial immunodiffusion  Serum Storiko et al. 1968
 
   
 
  Extracellular vesicle proteins    
     
 
Sample Isolation  Experimental method Vesiclepedia accession Reference
Plasma - Normal  Filtration|Size exclusion|Sucrose density gradient  Mass spectrometry [LTQ]|Western blotting|Immunoelectron Microscopy  Vesiclepedia_2 Bastos-Amador et al. 2012 
Plasma  Differential centrifugation|Filtration|Ultracenrifugation|Sucrose density gradient  Mass spectrometry [Q-TOF]  Vesiclepedia_2 Bastos-Amador et al. 2012 
 
   
 
 Architecture  
     
 
Domains Motifs
A2M   738 - 832
SP   1 - 23
 
   
 
 External links  
     
 
HPRD UniProt NetPath 
00072  P01023  NetPath_M2 
 
   
 
 
 Protein sequence  NP_000005.2
     
   
    MGKNKLLHPS LVLLLLVLLP TDASVSGKPQ YMVLVPSLLH TETTEKGCVL LSYLNETVTV SASLESVRGN RSLFTDLEAE NDVLHCVAFA VPKSSSNEEV MFLTVQVKGP TQEFKKRTTV
MVKNEDSLVF VQTDKSIYKP GQTVKFRVVS MDENFHPLNE LIPLVYIQDP KGNRIAQWQS FQLEGGLKQF SFPLSSEPFQ GSYKVVVQKK SGGRTEHPFT VEEFVLPKFE VQVTVPKIIT
ILEEEMNVSV CGLYTYGKPV PGHVTVSICR KYSDASDCHG EDSQAFCEKF SGQLNSHGCF YQQVKTKVFQ LKRKEYEMKL HTEAQIQEEG TVVELTGRQS SEITRTITKL SFVKVDSHFR
QGIPFFGQVR LVDGKGVPIP NKVIFIRGNE ANYYSNATTD EHGLVQFSIN TTNVMGTSLT VRVNYKDRSP CYGYQWVSEE HEEAHHTAYL VFSPSKSFVH LEPMSHELPC GHTQTVQAHY
ILNGGTLLGL KKLSFYYLIM AKGGIVRTGT HGLLVKQEDM KGHFSISIPV KSDIAPVARL LIYAVLPTGD VIGDSAKYDV ENCLANKVDL SFSPSQSLPA SHAHLRVTAA PQSVCALRAV
DQSVLLMKPD AELSASSVYN LLPEKDLTGF PGPLNDQDDE DCINRHNVYI NGITYTPVSS TNEKDMYSFL EDMGLKAFTN SKIRKPKMCP QLQQYEMHGP EGLRVGFYES DVMGRGHARL
VHVEEPHTET VRKYFPETWI WDLVVVNSAG VAEVGVTVPD TITEWKAGAF CLSEDAGLGI SSTASLRAFQ PFFVELTMPY SVIRGEAFTL KATVLNYLPK CIRVSVQLEA SPAFLAVPVE
KEQAPHCICA NGRQTVSWAV TPKSLGNVNF TVSAEALESQ ELCGTEVPSV PEHGRKDTVI KPLLVEPEGL EKETTFNSLL CPSGGEVSEE LSLKLPPNVV EESARASVSV LGDILGSAMQ
NTQNLLQMPY GCGEQNMVLF APNIYVLDYL NETQQLTPEI KSKAIGYLNT GYQRQLNYKH YDGSYSTFGE RYGRNQGNTW LTAFVLKTFA QARAYIFIDE AHITQALIWL SQRQKDNGCF
RSSGSLLNNA IKGGVEDEVT LSAYITIALL EIPLTVTHPV VRNALFCLES AWKTAQEGDH GSHVYTKALL AYAFALAGNQ DKRKEVLKSL NEEAVKKDNS VHWERPQKPK APVGHFYEPQ
APSAEVEMTS YVLLAYLTAQ PAPTSEDLTS ATNIVKWITK QQNAQGGFSS TQDTVVALHA LSKYGAATFT RTGKAAQVTI QSSGTFSSKF QVDNNNRLLL QQVSLPELPG EYSMKVTGEG
CVYLQTSLKY NILPEKEEFP FALGVQTLPQ TCDEPKAHTS FQISLSVSYT GSRSASNMAI VDVKMVSGFI PLKPTVKMLE RSNHVSRTEV SSNHVLIYLD KVSNQTLSLF FTVLQDVPVR
DLKPAIVKVY DYYETDEFAI AEYNAPCSKD LGNA